|
Psoriasis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Our observed genetic interaction between PGF and VEGFA appears relevant to psoriasis, a disease with an angiogenic basis, and may influence development of an antiangiogenic approach to treatment.
|
31545526 |
2020 |
|
Psoriasis
|
0.600 |
GeneticVariation
|
disease |
LHGDN |
Single-nucleotide polymorphisms and haplotypes in the VEGF receptor 3 gene and the haplotype GC in the VEGFA gene are associated with psoriasis in Koreans.
|
18094729 |
2008 |
|
Psoriasis
|
0.600 |
Biomarker
|
disease |
BEFREE |
In non-erythrodermic PF, VEGF positivity was similar to HI (P = 0.247), and lower than psoriasis (P = 0.049) and PV (P = 0.049).
|
29489039 |
2018 |
|
Psoriasis
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
To examine the role of Notch-1 signalling in the pathogenesis of psoriasis, Notch-1, DLL-4, Jagged-1, Hrt-1/Hrt-2, A-SAA, Factor VIII and vascular endothelial growth factor (VEGF) mRNA and/or protein expression in psoriasis skin biopsies, serum and dHMVEC were assessed by immunohistology, dual-immunofluorescence, real-time PCR, ELISA and Western blotting.
|
24330353 |
2014 |
|
Psoriasis
|
0.600 |
Biomarker
|
disease |
CTD_human |
In future, determination of VEGF gene polymorphisms and thus individual patient VEGF "signatures" may be used as a prognostic factor for psoriasis susceptibility/severity and as a means for optimizing treatment response.
|
16385345 |
2006 |
|
Psoriasis
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Vascular endothelial growth factor driving aberrant keratin expression pattern contributes to the pathogenesis of psoriasis.
|
28928080 |
2017 |
|
Psoriasis
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
In the current study, we assessed IL-37 in two well-known psoriasis models: a human keratinocyte cell line (HaCaT) and the keratin 14 VEGF-A-transgenic mouse model.
|
24453242 |
2014 |
|
Psoriasis
|
0.600 |
Biomarker
|
disease |
BEFREE |
How relevant are vascular endothelial growth factor and intercellular adhesion molecule in the systemic capillary leak syndrome of psoriasis?
|
29364440 |
2018 |
|
Psoriasis
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
This meta-analysis suggests the VEGF +405 C/G polymorphism confers susceptibility to psoriasis in Asians, and that the -460 C/T and -1154 A/G polymorphisms confer susceptibility to psoriasis in Europeans.
|
26600499 |
2015 |
|
Psoriasis
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Association of the CTG (-2578/-460/+405) haplotype within the vascular endothelial growth factor gene with early-onset psoriasis.
|
18937791 |
2008 |
|
Psoriasis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Due to the effect of inhibiting production of VEGF, acitretin can effectively treat psoriasis.
|
31148871 |
2020 |
|
Psoriasis
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Although increased expression of vascular endothelial growth factor protein was detected in the epidermis, the intensity of this staining was weak compared with the epidermal staining in psoriatic lesions and compared with the strong vascular endothelial growth factor mRNA signal in chronic wounds and psoriasis.
|
10886501 |
2000 |
|
Psoriasis
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Haplotype analysis suggests that the coexistence of the polymorphisms rs1799964 (TNF-α), rs2010963 (VEGF), rs833061 (VEGF), and rs6311 (5HT2A) may be a protective factor for psoriasis.
|
31148856 |
2020 |
|
Psoriasis
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Vascular endothelial growth factor gene polymorphisms increase the risk to develop psoriasis.
|
16630077 |
2006 |
|
Psoriasis
|
0.600 |
Biomarker
|
disease |
BEFREE |
These results suggest that alterations in the biology of VEGF may be involved in the pathogenesis of psoriasis.
|
14962110 |
2004 |
|
Psoriasis
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
We have found significantly increased serum levels of VEGF in patients with psoriasis compared with those in healthy controls (P = 0.008).
|
22176586 |
2013 |
|
Psoriasis
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Potential value as a novel marker of angiogenesis in patients with psoriasis is also evaluated by assessing possible relation of SCUBE-1 and 3 with disease activity in conjunction with vascular endothelial growth factor (VEGF) levels, as an established marker of angiogenesis.
|
28238185 |
2017 |
|
Psoriasis
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Also, up-regulation of psoriasis-associated cytokine profiles, including VEGF, was inhibited in the skin from K14-Raf:ER;K5-Cre.Stat3(flox/flox) mice following 4OHT treatment.
|
23870655 |
2013 |
|
Psoriasis
|
0.600 |
Biomarker
|
disease |
LHGDN |
In future, determination of VEGF gene polymorphisms and thus individual patient VEGF "signatures" may be used as a prognostic factor for psoriasis susceptibility/severity and as a means for optimizing treatment response.
|
16385345 |
2006 |
|
Psoriasis
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
In addition, VPF/VEGF is strongly expressed by epidermal keratinocytes in wound healing and psoriasis, disorders that are also characterized by increased microvascular permeability and angiogenesis.
|
7738351 |
1995 |
|
Psoriasis
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Topical application or subcutaneous injection of the Fib3 antibody decreased Psoriasis Area and Severity Index and VEGF expression in imiquimod-treated mice.
|
30146751 |
2019 |
|
Psoriasis
|
0.600 |
Biomarker
|
disease |
BEFREE |
The objective of the study was to elucidate the mechanism by which siRNA-mediated silencing of KRT16 affects keratinocyte proliferation and vascular endothelial growth factor (VEGF) secretion in psoriasis through the extracellular signal-related kinase (ERK) signaling pathway.
|
30942529 |
2019 |
|
Psoriasis
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
However, two other VEGF SNPs, rs833061, and rs699947, showed no association with psoriasis susceptibility.
|
28803785 |
2017 |
|
Psoriasis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Vascular endothelial growth factor (VEGF), the most critical angiogenic factor, is thought to play important roles during the pathogenesis of psoriasis and may be a promising target for treating psoriasis.
|
25227750 |
2014 |
|
Psoriasis
|
0.600 |
Biomarker
|
disease |
BEFREE |
These results imply that functional interactions among SP, IL-33, and mast cells leading to VEGF release contribute to inflammatory conditions, such as the psoriasis, a nonallergic hyperproliferative skin inflammatory disorder with a neurogenic component.
|
20160089 |
2010 |